Bench to Boardroom Speakers 2012
Sir Christopher Evans is regarded as one of Europe’s leading medical science entrepreneurs. He has a proven track record of establishing 45 successful, high-quality science companies, twenty of which have been taken public on 5 stock markets. Many of these companies have made substantial returns for their venture capital and institutional backers and employ more than 3,500 people. Of note is Chiroscience plc, started by Sir Christopher with $2 million in 1992 and grown to $1 billion by 1997 before merging with Celltech plc, which in turn merged with UCB to create one of Europe’s flagship bioscience enterprises. Sir Christopher’s considerable contributions to the biotechnology industry have been honoured with a Knighthood in the 2001 New Year’s Honours List and an OBE in the 1995 New Year’s Honours List. In 1987-1994, he created Cambridge’s first biomedical companies, starting the now famous Cambridge Cluster which has grown from Sir Chris’ earlier start ups to some 350 companies worth over $7 billion.
To view profile in full, please click here.
Dr Alison Campbell OBE
Alison Campbell’s career has largely been at the academic-industry interface, both in industry and the public sector. As an independent consultant, Alison specialises in academic/business collaboration and commercialisation. Her areas of expertise include strategic planning; project management; business development; and technology transfer. She also delivers training and development, nationally and internationally.
Most recently, as Managing Director for King’s College London Business Ltd she ran research commercialisation and enterprise across the range of academic disciplines at the university. Her remit has included business development and collaboration, IP management, consultancy, out-licensing, start-up company creation, clinical trials, executive education, research management and capturing the impact of research and innovation. Previously Alison worked for the UK Medical Research Council, with responsibility for commercialisation of the intra-mural research programme. She has been Division Director within the MRC, Technology Transfer Group and was latterly CEO at MRC Technology. A graduate of University College London, she completed her PhD in chemical biology at Imperial College London and then moved into industry as a research scientist at Celltech Ltd.
To view profile in full, please click here.